Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / NBRV - Nabriva Therapeutics' lefamulin application accepted for review in China

NBRV - Nabriva Therapeutics' lefamulin application accepted for review in China

Nabriva Therapeutics plc
Nabriva Therapeutics (NBRV) announces that its partner, Sumitomo Pharmaceuticals’ new drug application (NDA) to market oral and intravenous (IV) formulations of lefamulin for the treatment of community-acquired pneumonia (CAP) in adults has been accepted for review in China. "This is the 6th global filing for lefamulin. To date there have been 4 approvals and two applications pending review,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.

For further details see:

Nabriva Therapeutics' lefamulin application accepted for review in China
Stock Information
Company Name: Nabriva Therapeutics plc
Stock Symbol: NBRV
Market: NASDAQ
Menu
NBRV NBRV Quote NBRV Short NBRV News NBRV Articles NBRV Message Board
Get NBRV Alerts

News, Short Squeeze, Breakout and More Instantly...